<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3442">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04816071</url>
  </required_header>
  <id_info>
    <org_study_id>261678</org_study_id>
    <nct_id>NCT04816071</nct_id>
  </id_info>
  <brief_title>Essential Amino Acid Supplementation in Older Adult COVID-19 Patients</brief_title>
  <official_title>Essential Amino Acid Supplementation in Older Adult COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 4-week treatment of essential amino acids or placebo to participants with: 1) negative&#xD;
      COVID-19 test with exposure, or 2) positive COVID-19 test and no or mild symptoms. The study&#xD;
      team will measure change in symptoms. Participants will complete symptom surveys for 4 weeks&#xD;
      and once at 8 and 12 weeks as well as pre- and post-assessments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In people who have been exposed to COVID-19 and have been tested (positive or negative) with&#xD;
      no to mild symptoms, the study team will administer a treatment of essential amino acids&#xD;
      (EAA). The study team will examine if this treatment compared to placebo will reduce the&#xD;
      development, length and the severity of symptoms. Participants will consume the treatment or&#xD;
      placebo for 4 weeks, and will complete symptom surveys, as well as pre- and post-assessments.&#xD;
      Individuals who receive a COVID vaccination will continue to complete symptom surveys for 1&#xD;
      week and take the essential amino acid supplementation for 2 weeks following a vaccination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>Decrease in EAA group symptom score compared to placebo by 25%</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>EAA - non-vaccinated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 g/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - non-vaccinated</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>18 g/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EAA - vaccinated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>18 g/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - vaccinated</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>18 g/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Essential amino acids</intervention_name>
    <description>Dietary Supplement</description>
    <arm_group_label>EAA - non-vaccinated</arm_group_label>
    <arm_group_label>EAA - vaccinated</arm_group_label>
    <other_name>EAA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Control</description>
    <arm_group_label>Placebo - non-vaccinated</arm_group_label>
    <arm_group_label>Placebo - vaccinated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Exposure to COVID-19 in the last 60 days with no symptoms, with a COVID negative test&#xD;
             Close contact: within 6 feet of a COVID-19 positive person for more than a few minutes&#xD;
             without wearing PPE, or having direct contact with infectious secretions without PPE&#xD;
&#xD;
          -  Positive COVID-19 test with or without symptoms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  COVID-19 positive hospitalized patient&#xD;
&#xD;
          -  Patients who have symptoms of COVID but have not been tested.&#xD;
&#xD;
          -  Unable to tolerate oral intake&#xD;
&#xD;
          -  In hospice or palliative care&#xD;
&#xD;
          -  Unstable medical or psychiatric condition&#xD;
&#xD;
          -  Other criteria deemed acceptable by principle investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gohar Azhar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amino acid supplement</keyword>
  <keyword>Dietary supplement</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

